Abstract
This study evaluated the anti-hypertensive efficacy, tolerability and effects on left ventricular mass of losartan, a selective angiotensin II receptor antagonist, after 22 months in patients with essential hypertension. The study included 77 hypertensive patients who were randomised at baseline to 22 months double-blind once-daily treatment with losartan 50 mg (L group n = 44 patients, mean age 54 ± 9 years) or hydrochlorothiazide 25 mg (HCTZ group, n = 33 patients, mean age 56 ± 7 years). Routine haematology, blood chemistry, standard electrocardiography, echocardiography and ambulatory non-invasive 24-h blood pressure (BP) monitoring were performed at baseline and after 10 and 22 months. The results showed good tolerability and a significant mean systolic and diastolic BP reduction in all groups (L group: 22 mm Hg and 11 mm Hg; HCTZ group: 11 mm Hg and 7 mm Hg, respectively for systolic and diastolic mean BP). Moreover, a remarkable reduction in left ventricular mass index was reached after 10 and 22 months only in the L group (L group: Δ = –11 g/m2, P <0.02; hctz group: δ = –5 g/m2, P = 0.38). In conclusion, losartan was well tolerated and produced a significant reduction in BP and left ventricular mass in hypertensive patients
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tedesco, M., Ratti, G., Aquino, D. et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 12, 505–510 (1998). https://doi.org/10.1038/sj.jhh.1000685
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000685
Keywords
This article is cited by
-
The role of renin–angiotensin–aldosterone system inhibition in the regression of hypertensive left ventricular hypertrophy: the evidence of the last three decades
Drugs & Therapy Perspectives (2020)
-
The effects of combined treatment of losartan and ramipril on hypertension and related complications
Journal of Pharmaceutical Investigation (2020)
-
Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation
Journal of Human Hypertension (2016)
-
Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials
Journal of Human Hypertension (2013)
-
Effects of combined therapy of Xuezhikang Capsule (血脂康胶囊) and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence
Chinese Journal of Integrative Medicine (2010)